This article is more than 5 years old. Information may no longer be current.

Blue Belt Technologies granted FDA clearance for patellofemoral offering

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Blue Belt Technologies announced it has received 510(k) clearance to market the Navio patellofemoral joint replacement application.

As the company’s latest expansion for the Navio surgical system, the patellofemoral joint replacement application has broadened the surgical system’s indications from unicondylar knee replacement to provide a range of options for partial knee replacement.

Patellofemoral joint replacement allows the company to offer robotics-assisted surgery to a broader population of patients with early- to mid-stage osteoarthritis who would opt for partial knee replacement over total knee arthroplasty, according to a company press release.

 “We focus our technology development efforts on clinically relevant applications that can benefit from reproducible precision. Adding patellofemoral replacement was the logical next step for us,” Eric Timko, president and CEO of Blue Belt Technologies, said in the press release.